Y |
| C49487 | CDISC CT | 2023-03-31 |
4 | XYZ | TS | 1 |
| AGEMAX | Planned Maximum Age of Subjects | PINF |
|
|
|
|
5 | XYZ | TS | 1 |
| AGEMIN | Planned Minimum Age of Subjects | P18Y |
|
| ISO 8601 |
|
6 | XYZ | TS | 1 | PA | DCUTDTC | Data Cutoff Date | 2010-04-10 |
|
| ISO 8601 |
|
7 | XYZ | TS | 1 | PA | DCUTDESC | Data Cutoff Description | PRIMARY ANALYSIS |
|
|
|
|
8 | XYZ | TS | 1 |
| FCNTRY | Planned Country of Investigational Sites | USA |
|
| ISO 3166-1 Alpha-3 |
|
9 | XYZ | TS | 2 |
| FCNTRY | Planned Country of Investigational Sites | CAN |
|
| ISO 3166-1 Alpha-3 |
|
10 | XYZ | TS | 1 |
| INDIC | Trial Disease/Condition Indication | Tobacco smoking consumption |
| 266918002 | SNOMED | 2011-03 |
11 | XYZ | TS | 1 |
| LENGTH | Trial Length | P3M |
|
| ISO 8601 |
|
12 | XYZ | TS | 1 |
| NARMS | Planned Number of Arms | 3 |
|
|
|
|
13 | XYZ | TS | 1 |
| OBJPRIM | Trial Primary Objective | Change in concentration of Nicotine in urine from baseline |
|
|
|
|
14 | XYZ | TS | 1 |
| OBJSEC | Trial Secondary Objective | Change in concentration of Cotinine in urine from baseline |
|
|
|
|
15 | XYZ | TS | 1 |
| PLANSUB | Planned Number of Subjects | 300 |
|
|
|
|
16 | XYZ | TS | 1 |
| RANDOM | Trial is Randomized | Y |
| C49488 | CDISC CT | 2023-03-31 |
17 | XYZ | TS | 1 |
| REGID | Registry Identifier | NCT123456789 |
| NCT123456789 | ClinicalTrials.gov |
|
18 | XYZ | TS | 2 |
| REGID | Registry Identifier | XXYYZZ456 |
| XXYYZZ456 | EudraCT |
|
19 | XYZ | TS | 1 |
| SENDTC | Study End Date | 2011-04-01 |
|
| ISO 8601 |
|
20 | XYZ | TS | 1 |
| SEXPOP | Sex of Participants | BOTH |
| C49636 | CDISC CT | 2023-03-31 |
21 | XYZ | TS | 1 |
| APPLCNT | | TobaccoCo |
| | D-U-N-S NUMBER |
|
22 | XYZ | TS | 1 |
| STOPRULE | Study Stop Rules | NONE |
|
|
|
|
23 | XYZ | TS | 1 |
| TBLIND | Trial Blinding Schema | DOUBLE BLIND |
| C15228 | CDISC CT | 2023-03-31 |
| XYZ | TS | 1 |
| TCNTRL | Control Type | ACTIVE |
| C49649 | CDISC CT | 2023-03-31 |
25 | XYZ | TS | 1 |
| TITLE | Trial Title | A 3 month study of tobacco biomarkers in subjects using ENDS devices |
|
|
|
|
26 | XYZ | TS | 1 |
| TDIGRP | Diagnosis Group |
| NA |
|
|
|
27 | XYZ | TS | 1 |
| TINDTP | Trial Intent Type |
| NA | C49656 | CDISC CT | 2023-03-31 |
28 | XYZ | TS | 1 |
| TPHASE | Trial Phase Classification | NOT APPLICABLE |
|
|
|
|
29 | XYZ | TS | 1 |
| TTYPE | Trial Type | PHARMACOKINETIC |
| C49663 | CDISC CT | 2023-03-31 |
30 | XYZ | TS | 1 |
| STYPE | Study Type | INTERVENTIONAL |
| C98388 | CDISC CT | 2023-03-31 |
31 | XYZ | TS | 1 |
| SDTIGVER | SDTM IG Version | 3.4 |
|
|
|
|
32 | XYZ | TS | 1 |
| STDMVER | SDTM Version | 1.4 |
|
|
|
|
33 | XYZ | TS | 1 |
| TIGVER | Tobacco IG Version | 1.0 |
|
|
|
|